Details of the Drug

General Information of Drug (ID: DMUIQUK)

Drug Name

GS-5816

Indication

Disease Entry	ICD 11	Status	REF
Chronic HCV-1 infection	1E51.1	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C49H54N8O8
Canonical SMILES: CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC
InChI: 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
InChIKey: FHCUMDQMBHQXKK-CDIODLITSA-N

Cross-matching ID

References

1	ClinicalTrials.gov (NCT02336139) A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use. U.S. National Institutes of Health.